Private Third Party Payor Programs definition

Private Third Party Payor Programs means all U.S. third party payor programs in which any Credit Party or its Subsidiaries participates, including Managed Care Plans, or any other private insurance programs, but excluding all Governmental Payor Programs.
View Source
Private Third Party Payor Programs has the meaning set forth in Section 5.22(c).
View Source
Private Third Party Payor Programs as defined in Section 4.22.
View Source

Examples of Private Third Party Payor Programs in a sentence

  • For purposes of this Agreement, a “Private Third Party Payor” means private insurers and any other person or entity which presently or in the future maintains Private Third Party Payor Programs.

  • To the extent applicable to the Borrowers and their Subsidiaries in the conduct of their business, each of the Borrowers and their Subsidiaries shall maintain its qualification for participation in, and payment under, Governmental Third Party Payor Programs and Private Third Party Payor Programs, that provide for payment or reimbursement for services, except to the extent such loss or relinquishment would not reasonably be expected to have a Material Adverse Effect.

  • No Credit Party or any of its Subsidiaries bills or receives reimbursement from any Governmental Payor Program or any Private Third Party Payor Programs.

  • To the extent applicable to Borrower or any of its Subsidiaries in the conduct of their business, each of Borrower and its Subsidiaries shall maintain its qualification for participation in, and payment under, Governmental Third Party Payor Programs and Private Third Party Payor Programs, that provide for payment or reimbursement for services, except to the extent such loss or relinquishment could not reasonably be expected to have a Material Adverse Event.

  • Each of the Borrowers and their Subsidiaries, to the extent that it is billing the related payor, has the requisite provider number or other Governmental Authorization to ▇▇▇▇ under Medicare, the respective Medicaid program in the state or states in which such entity operates, or Private Third Party Payor Programs.

  • To the extent applicable to the Borrowers and their Subsidiaries in the conduct of their business, each of the Borrowers and their Subsidiaries shall maintain its qualification for participation in, and payment under, Governmental Third Party Payor Programs and Private Third Party Payor Programs, that provide for payment or reimbursement for services, except to the extent such loss or relinquishment would not reasonably be expected to have a Material Adverse Event.


More Definitions of Private Third Party Payor Programs

Private Third Party Payor Programs means all U.S. third party payor programs in which any Credit Party or its Subsidiaries participates, including Managed Care Plans, or any other private insurance programs, but excluding all Governmental Payor Programs. “Product” means, collectively, (a)(i) the pharmaceutical product known as XDEMVY® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03 (and foreign-named equivalents) and any successors thereto, including the product approved by the FDA under NDA 217603 and any supplements thereto (ii) any pharmaceutical product for the treatment of Demodex blepharitis, and (iii) any pharmaceutical product that contains lotilaner (but excluding TP- 05), including as an active ingredient thereof, in each case of sub-clauses (i), (ii) and (iii) above, in any dosage form, dosing regimen, strength or route of administration, in each case, intended for use in humans; and (b) any Competing Product pursuant to Section 5.2(d). “Product Net Sales” means, solely with respect to sales of Product described in clause (a)(i) of the definition of Product, as of any date of determination, the net consolidated product revenue (consistent with the calculation of same in the Borrower’s financial statements) of Borrower and its Subsidiaries of such Product for the period in question (excluding, for the avoidance of doubt, any (i) upfront or milestone payments received by Borrower or any of its Subsidiaries, (ii) advancements, payments or reimbursements of expenses of Borrower or any of its Subsidiaries, and (iii) any other non-sales-based revenue or proceeds received by Borrower or any of its Subsidiaries), as the context dictates, determined on a consolidated basis in accordance with GAAP as set forth in Borrower’s financial statements or as otherwise evidenced in a manner reasonably satisfactory to the Required Lenders. “Register” is defined in Section 2.8(a). “Registered Organization” means any “registered organization” as defined in the Code with such additions to such term as may hereafter be made. “Regulatory Agency” means a U.S. or foreign Governmental Authority with responsibility for the approval of the marketing and sale of pharmaceuticals or other regulation of pharmaceuticals, or otherwise having authority to regulate Product, including the FDA, Health Canada, European Medicines Agency, National Medical Products Administration in China and Medicines and Healthcare products Regulatory Agency in the UK. “Regulatory Approvals or Licensures” means all U.S., C...
View Source
Private Third Party Payor Programs means all U.S. third party payor programs in which any Credit Party or its Subsidiaries participates, including Managed Care Plans, or any other private insurance programs, but excluding all Governmental Payor Programs. “Product” means, collectively, (a)(i) the pharmaceutical product known as XDEMVY® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03 (and foreign-named equivalents) and any successors thereto, including the product approved by the FDA under NDA 217603 and any supplements thereto (ii) any pharmaceutical product for the treatment of Demodex blepharitis, and (iii) any pharmaceutical product that contains lotilaner (but excluding TP- 05), including as an active ingredient thereof, in each case of sub-clauses (i), (ii) and (iii) above, in any dosage form, dosing regimen, strength or route of administration, in each case, intended for use in humans; and (b) any Competing Product pursuant to Section 5.2(d). “Product Net Sales” means, solely with respect to sales of Product described in clause (a)(i) of the definition of Product, as of any date of determination, the net consolidated product revenue (consistent with the calculation of same in the Borrower’s financial statements) of Borrower and its Subsidiaries of such Product for the period in question (excluding, for the avoidance of doubt, any (i) upfront or milestone payments received by Borrower or any of its Subsidiaries, (ii) advancements, payments or reimbursements of expenses of Borrower or any of its Subsidiaries, and (iii) any other non-sales-based revenue or proceeds received by Borrower or any of its Subsidiaries), as the context dictates, determined on a consolidated basis in accordance with GAAP as set forth in Borrower’s financial statements or as otherwise evidenced in a manner reasonably satisfactory to the Required Lenders. “Register” is defined in Section 2.8(a). “Registered Organization” means any “registered organization” as defined in the Code with such additions to such term as may hereafter be made. “Regulatory Agency” means a U.S. or foreign Governmental Authority with responsibility for the approval of the marketing and sale of pharmaceuticals or other regulation of pharmaceuticals, or otherwise having authority to regulate Product, including the FDA, Health Canada, European Medicines Agency, National Medical Products Administration in China and Medicines and Healthcare products Regulatory Agency in the UK. “Regulatory Approvals or Licensures” means all U.S., C...
View Source